Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BioAtla, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, OCT. 03, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS USING ITS PROPRIETARY CAB PLATFORM FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT CLINICAL DATA FOR ITS INVESTIGATIONAL AXL-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), MECBOTAMAB VEDOTIN (BA3011), WILL BE PRESENTED AT THE UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2025 ANNUAL MEETING TO BE HELD AT NATIONAL HARBOR, MD FROM NOVEMBER 5-9, 2025.

BIOATLA TO PRESENT CLINICAL DATA FOR MECBOTAMAB VEDOTIN (BA3011) IN SOFT TISSUE SARCOMA AT SITC 2025

FDA ALIGNMENT ON PHASE 3 OZURIFTAMAB VEDOTIN (OZ-V) TRIAL DESIGN, INCLUDING DOSING REGIMEN AND ENDPOINTS TO SUPPORT POTENTIAL ACCELERATED APPROVAL COMPANY CONTINUES PREPARATIONS FOR ENABLING INITIATION OF THE PHASE 3 STUDY WITH THE GOAL OF ADVANCING THE STUDY WITH A STRATEGIC PARTNER EARLY NEXT YEAR COMPANY MAINTAINS PREVIOUS GUIDANCE FOR COMPLETION OF A STRATEGIC PARTNERSHIP WITH ONE OF OUR ADVANCED CLINICAL ASSETS THIS YEAR SAN DIEGO, SEPT. 08, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS USING ITS PROPRIETARY CAB PLATFORM FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED OUTCOMES FROM ITS TYPE B MEETING WITH THEUNITED STATES FOOD AND DRUG ADMINISTRATION(FDA).

BIOATLA ANNOUNCES REGULATORY UPDATE ON CLINICAL DEVELOPMENT PLAN FOR OZURIFTAMAB VEDOTIN IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) FOLLOWING PRODUCTIVE TYPE B (END OF PHASE 2) MEETING WITH FDA

CAB-EPCAM X CAB-CD3 BISPECIFIC T-CELL ENGAGER (TCE) (BA3182) PHASE 1 DOSE-ESCALATION STUDY ONGOING, CURRENTLY DOSING 1.2 MG COHORT; PHASE 1 DATA READOUT

BIOATLA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

SAN DIEGO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF

BIOATLA TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTSAND PROVIDE BUSINESS HIGHLIGHTS ON AUGUST 7, 2025

SAN DIEGO, JULY 17, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB) (THE COMPANY OR BIOATLA), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED AN ORAL PRESENTATION AT THE UPCOMING 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) TAT ASIA MEETING TO BE HELD IN HONG KONG SAR, CHINA FROM JULY 1820, 2025. ORAL PRESENTATION DETAILS:    TITLE:  FIRST-IN-HUMAN PHASE I STUDY OF A DUAL-CONDITIONALLY ACTIVE BIOLOGIC (CAB) EPCAM X CD3 BISPECIFIC T-CELL ENGAGER (TCE), BA3182, IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AUTHORS:  JENNIFER B.

BIOATLA ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) TAT ASIA MEETING

ADVERSE EVENTS WERE GENERALLY LOW-GRADE, TRANSIENT, AND READILY MANAGEABLE ACHIEVED PRELIMINARY EVIDENCE OF PROLONGED TUMOR CONTROL AND TUMOR REDUCTIONS IN HEAVILY PRETREATED ADENOCARCINOMA PATIENTS DOSE ESCALATION NOW CONTINUING AT 1.2 MG WEEKLY BY SUBCUTANEOUS FLAT DOSING SAN DIEGO, JULY 03, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB) (THE COMPANY OR BIOATLA), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY PRESENTED FIRST-IN-HUMAN DATA IN A POSTER TITLED PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF A DUAL-CONDITIONALLY BINDING CAB-EPCAM X CAB-CD3 BISPECIFIC T-CELL ENGAGER, BA3182, IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) GASTROINTESTINAL CANCERS CONGRESS BEING HELD IN BARCELONA, SPAIN FROM JULY 25, 2025. IN THE ONGOING PHASE 1 DOSE-ESCALATION CLINICAL TRIAL, AS OF JUNE 20, 2025, 39 PATIENTS WITH HEAVILY PRETREATED METASTATIC ADENOCARCINOMA WERE DOSED IN COHORTS RANGING FROM 0.0026 MG TO 0.6 MG BA3182 QW, WITH EITHER 0, 1, OR 2 PRIMING DOSE(S) DELIVERED FOUR TO SEVEN DAYS PRIOR TO TREATMENT DOSING.

BIOATLA PRESENTS DATA FROM ONGOING DOSE ESCALATION OF BA3182, DUAL-CONDITIONALLY BINDING EPCAM X CD3 BISPECIFIC T-CELL ENGAGER, IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) GASTROINTESTINAL CANCERS CONGRESS

45% OVERALL RESPONSE RATE (ORR) AND A 100% DISEASE CONTROL RATE (DCR) IN HPV+ OPSCC PATIENTS TREATED WITH A MEDIAN OF 3 PRIOR LINES OF THERAPY MARKED UNMET NEED EXISTS IN 2L+ HPV+ OPSCC PATIENTS; STANDARD OF CARE AGENTS (METHOTREXATE, DOCETAXEL, OR CETUXIMAB) REPORT AN ORR OF 3.4% PLAN TO FINALIZE PHASE 3 TRIAL DESIGN IN 2L+ HPV+ OPSCC WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SAN DIEGO, JUNE 02, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB) (THE COMPANY), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED DATA IN A POSTER TITLED, PHASE 2 TRIAL OF OZURIFTAMAB VEDOTIN (OZ-V), A CONDITIONALLY BINDING CAB-ROR2-ADC, IN PATIENTS WITH HEAVILY PRETREATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. THE POSTER WILL BE PRESENTED TODAY AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING AT THE MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS.

BIOATLA PRESENTS PHASE 2 OZURIFTAMAB VEDOTIN (OZ-V) CLINICAL TRIAL DATA DEMONSTRATING COMPELLING ANTITUMOR ACTIVITY IN HPV-ASSOCIATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (HPV+ OPSCC) AT THE 1.8 MG/KG Q2W DOSING REGIMEN

CAB-EPCAM X CAB-CD3 (BA3182) PHASE 1 DOSE-ESCALATION STUDY ONGOING, DOSED FIRST THREE PATIENTS AT 300 MICROGRAMS; DATA READOUT EXPECTED MID-2025 WITH DOSE

BIOATLA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

SAN DIEGO, APRIL 29, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT IT PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON TUESDAY, MAY 6, 2025 AT 4:30 P.M. ET TO DISCUSS ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDE BUSINESS HIGHLIGHTS.

BIOATLA TO ANNOUNCE FIRST QUARTER 2025 FINANCIAL RESULTSAND PROVIDE BUSINESS HIGHLIGHTS ON MAY 6, 2025

DUBLIN, MARCH 04, 2025 (GLOBE NEWSWIRE) -- THE "AXL INHIBITORS - PIPELINE INSIGHT, 2025" DRUG PIPELINES HAS BEEN ADDED TO RESEARCHANDMARKETS.COM'S OFFERING. THIS REPORT PROVIDES COMPREHENSIVE INSIGHTS ABOUT 16+ COMPANIES AND 20+ PIPELINE DRUGS IN AXL INHIBITORS PIPELINE LANDSCAPE. IT COVERS THE PIPELINE DRUG PROFILES, INCLUDING CLINICAL AND NONCLINICAL STAGE PRODUCTS. IT ALSO COVERS THE THERAPEUTICS ASSESSMENT BY PRODUCT TYPE, STAGE, ROUTE OF ADMINISTRATION, AND MOLECULE TYPE. IT FURTHER HIGHLIGHTS THE INACTIVE PIPELINE PRODUCTS IN THIS SPACE. REPORT HIGHLIGHTS COMPANIES AND ACADEMICS ARE WORKING TO ASSESS CHALLENGES AND SEEK OPPORTUNITIES THAT COULD INFLUENCE AXL INHIBITORS R&D. THE THERAPIES UNDER DEVELOPMENT ARE FOCUSED ON NOVEL APPROACHES TO TREAT/IMPROVE AXL INHIBITORS. AXL INHIBITORS EMERGING DRUGS CHAPTERS THIS SEGMENT OF THE AXL INHIBITORS REPORT ENCLOSES ITS DETAILED ANALYSIS OF VARIOUS DRUGS IN DIFFERENT STAGES OF CLINICAL DEVELOPMENT, INCLUDING PHASE II, I, PRECLINICAL AND DISCOVERY. IT ALSO HELPS TO UNDERSTAND CLINICAL TRIAL DETAILS, EXPRESSIVE PHARMACOLOGICAL ACTION, AGREEMENTS AND COLLABORATIONS, AND THE LATEST NEWS AND PRESS RELEASES. EMERGING DRUGS

AXL INHIBITORS PIPELINE RESEARCH REPORT 2025: FEATURES INSIGHTS ON 16+ COMPANIES AND 20+ PIPELINE DRUGS, INCLUDING CABOZANTINIB (EXELIXIS/IPSEN), BA 3011 (BIOATLA) & TP-0903 (SUMITOMO DAINIPPON PHARMA ONCOLOGY)

BioAtla, Inc.

BCAB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BioAtla, Inc.

BCAB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BCAB